A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy

Sanmamed, 2019, A paradigm shift in cancer immunotherapy: from enhancement to normalization, Cell, 176, 677, 10.1016/j.cell.2019.01.008 Bagchi, 2021, Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance, Annu Rev. Pathol., 16, 223, 10.1146/annurev-pathol-042020-042741 Jiang, 2020, Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade, Front. Immunol., 11, 339, 10.3389/fimmu.2020.00339 Furukawa, 1875, Peptides that immunoactivate the tumor microenvironment, Biochim. Biophys. Acta Rev. Cancer, 2021 Chang, 2015, Blocking of the PD-1/PD-L1 Interaction by a D-peptide antagonist for cancer immunotherapy, Angew. Chem. Int. Ed. Engl., 54, 11760, 10.1002/anie.201506225 Li, 2021, An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy, J. Control Release, 334, 376, 10.1016/j.jconrel.2021.04.036 Zhai, 2021, Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy, Sci. China Life Sci., 64, 548, 10.1007/s11427-020-1740-8 Cheng, 2018, Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy, Nano Lett., 18, 3250, 10.1021/acs.nanolett.8b01071 Hu, 2019, Tumor lysate-loaded lipid hybrid nanovaccine collaborated with an immune checkpoint antagonist for combination immunotherapy, Adv. Healthc. Mater., 8, 10.1002/adhm.201800837 Sun, 2018, PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer, Drug Deliv., 25, 1746, 10.1080/10717544.2018.1509907 Hu, 2021, Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors, Acta Pharm. Sin. B Yin, 2021, Rational design of potent peptide inhibitors of the PD-1:PD-L1 interaction for cancer immunotherapy, J. Am. Chem. Soc., 143, 18536, 10.1021/jacs.1c08132 Pan, 2021, Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation, Eur. J. Med. Chem., 213, 10.1016/j.ejmech.2021.113170 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Zhang, 2016, Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy, JAMA Oncol., 2, 1403, 10.1001/jamaoncol.2016.2450 Teng, 2018, Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review, Cancer Lett., 414, 166, 10.1016/j.canlet.2017.11.014 Randolph, 2017, The lymphatic system: integral roles in immunity, Annu Rev. Immunol., 35, 31, 10.1146/annurev-immunol-041015-055354 Schaaf, 2018, Defining the role of the tumor vasculature in antitumor immunity and immunotherapy, Cell Death Dis., 9, 115, 10.1038/s41419-017-0061-0 Greenberg, 2008, A role for VEGF as a negative regulator of pericyte function and vessel maturation, Nature, 456, 809, 10.1038/nature07424 Dirkx, 2003, Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression, Cancer Res., 63, 2322 Dirkx, 2006, Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors, FASEB J., 20, 621, 10.1096/fj.05-4493com Al-Abd, 2017, Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - a review, J. Adv. Res, 8, 591, 10.1016/j.jare.2017.06.006 Lugano, 2020, Tumor angiogenesis: causes, consequences, challenges and opportunities, Cell Mol. Life Sci., 77, 1745, 10.1007/s00018-019-03351-7 Ying, 2016, Stabilized heptapeptide A7R for enhanced multifunctional liposome-based tumor-targeted drug delivery, ACS Appl. Mater. Interfaces, 8, 13232, 10.1021/acsami.6b01300 Tada, 2018, Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment, J. Immunother. Cancer, 6, 106, 10.1186/s40425-018-0403-1 Gao, 2020, Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic, Curr. Cancer Drug Targets, 20, 3, 10.2174/1568009619666191114110359 Wu, 2018, Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy, OncoTargets Ther., 11, 6901, 10.2147/OTT.S172042 Allen, 2017, Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation, Sci. Transl. Med., 9, 10.1126/scitranslmed.aak9679 Rodriguez-Ruiz, 2019, Immune mechanisms mediating abscopal effects in radioimmunotherapy, Pharm. Ther., 196, 195, 10.1016/j.pharmthera.2018.12.002 Spiotto, 2016, The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications, Sci. Immunol., 1, 10.1126/sciimmunol.aag1266 Lee, 2009, Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment, Blood, 114, 589, 10.1182/blood-2009-02-206870 Kordbacheh, 2018, Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms, Ann. Oncol., 29, 301, 10.1093/annonc/mdx790 Deng, 2014, Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice, J. Clin. Invest., 124, 687, 10.1172/JCI67313 Dovedi, 2014, Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade, Cancer Res., 74, 5458, 10.1158/0008-5472.CAN-14-1258 Zhai, 2019, In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1, Methods Enzym., 629, 361, 10.1016/bs.mie.2019.05.051 Khalsa, 2020, Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types, Nat. Commun., 11, 3912, 10.1038/s41467-020-17704-5 Larsen, 2016, Albumin-based drug delivery: harnessing nature to cure disease, Mol. Cell Ther., 4, 3, 10.1186/s40591-016-0048-8 Ma, 2015, A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis, Sci. Rep., 5, 13595, 10.1038/srep13595 Feng, 2018, in vivoDevelopment of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased anti-tumor efficacy, Theranostics, 8, 2094, 10.7150/thno.22069 Doti, 2021, Recent applications of retro-inverso peptides, Int. J. Mol. Sci., 22, 10.3390/ijms22168677 Tugyi, 2005, Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide, Proc. Natl. Acad. Sci. USA, 102, 413, 10.1073/pnas.0407677102 Xie, 2015, Retro-inverso bradykinin opens the door of blood-brain tumor barrier for nanocarriers in glioma treatment, Cancer Lett., 369, 144, 10.1016/j.canlet.2015.08.010 Knudsen, 2019, The discovery and development of liraglutide and semaglutide, Front. Endocrinol., 10, 155, 10.3389/fendo.2019.00155 Xie, 2010, An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life, Antimicrob. Agents Chemother., 54, 191, 10.1128/AAC.00976-09 Wang, 2020, CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy, J. Immunother. Cancer, 8, 10.1136/jitc-2020-000905 Gou, 2021, Engineered nanovaccine targeting Clec9a dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist, Nano Lett., 21, 9939, 10.1021/acs.nanolett.1c03243 Timaner, 2020, Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1, Oncogene, 39, 187, 10.1038/s41388-019-0971-7 Solberg, 2008, Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy, Int. J. Radiat. Oncol. Biol. Phys., 72, 918, 10.1016/j.ijrobp.2008.06.1925 Kaspar, 2013, Future directions for peptide therapeutics development, Drug Disco. Today, 18, 807, 10.1016/j.drudis.2013.05.011 Lee, 2019, Review on current advances in peptide drug development and design, Int. J. Mol. Sci., 20 Zhou, 2020, A novel d-peptide identified by mirror-image phage display blocks TIGIT/PVR for cancer, Angew. Chem. Int. Ed. Engl., 59, 15114, 10.1002/anie.202002783 Zhai, 2020, A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8 T cell responses, Acta Pharm. Sin. B, 10, 1047, 10.1016/j.apsb.2020.01.005 Bruno, 2013, Basics and recent advances in peptide and protein drug delivery, Ther. Deliv., 4, 1443, 10.4155/tde.13.104 Sleep, 2015, Albumin and its application in drug delivery, Expert Opin. Drug Deliv., 12, 793, 10.1517/17425247.2015.993313 Chen, 2017, Novel “add-on” molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents, J. Nucl. Med, 58, 590, 10.2967/jnumed.116.182097 Han, 2017, MMP-2-sensitive HA end-conjugated poly(amidoamine) dendrimers via click reaction to enhance drug penetration into solid tumor, ACS Appl. Mater. Interfaces, 9, 42459, 10.1021/acsami.7b10098 Yao, 2018, MMP-responsive ‘smart’ drug delivery and tumor targeting, Trends Pharm. Sci., 39, 766, 10.1016/j.tips.2018.06.003 Hadler-Olsen, 2013, Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets, Tumour Biol., 34, 2041, 10.1007/s13277-013-0842-8 Goel, 2011, Normalization of the vasculature for treatment of cancer and other diseases, Physiol. Rev., 91, 1071, 10.1152/physrev.00038.2010 Gao, 2015, Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model, Proc. Natl. Acad. Sci. USA, 112, 14676, 10.1073/pnas.1512570112